OneMain Financial reported Q3 earnings with adjusted EPS of $1.51, missing consensus and declining year-over-year, causing shares to fall 5%. However, revenue grew 7% driven by managed receivables reaching $28.1 billion, the fastest growth pace expected in 2026. The company's 100-year history, transparency, and monthly servicer reports set it apart, supporting long-term confidence. With a 7.4% yield and low correlation to AI-driven trends, OneMain remains a Strong Buy with a fair value estimate of $67.50-$72.00.
OneMain Holdings provides context for financial market activity. For readers following Financials, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: Of 142 priced Financials-sector US stocks, 126 rose and 16 fell today. Notable movers include BMNR at USD 22.14 with a 7.87% increase and SEZL at USD 131.87 with a 7.71% rise, despite 97% sell order activity. DB traded at USD 36.54, up 7.38%, with 100% sell orders and a typical hold time of 81 days on Pluang.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
